New therapeutic options in the National Cholesterol Education Program Adult Treatment Panel III

American Journal of Managed Care

Volumn 8, Issue 12 SUPPL., 2002, Pages

  Talbert, Robert L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BILE ACID SEQUESTRANT; CHOLESTEROL; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; STATIN DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; CLASSIFICATION; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIET THERAPY; DISEASE MARKER; DRUG TARGETING; DYSLIPIDEMIA; HEALTH CARE COST; HEALTH EDUCATION; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; METABOLIC DISORDER; MORBIDITY; MORTALITY; PATIENT CARE; PATIENT CODING; PATIENT COMPLIANCE; PATIENT SELECTION; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SCORING SYSTEM; SMOKING;

ADULT; AGED; CHOLESTEROL; CORONARY DISEASE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT EDUCATION; PRACTICE GUIDELINES; RISK FACTORS; SMOKING; UNITED STATES;

EID: 0036740491     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. American Heart Association. 2002 Heart and Stroke Statistical Update. American Heart Association: Dallas, Tex; 2002.
2. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
4. Downs JR, Clearfield M, Weis S, et al, for the Air Force/Texas Coronary Atherosclerosis Prevention Study. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
5. Rubins HB, Robins SJ, Collins D, et al, for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410-418.
6. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
7. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
8. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
9. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988;148:36-69.
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
12. Hoerger TJ, Bala MV, Bray JW, Wilcosky TC, LaRosa J. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol. 1998;82:61-65.
13. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459-467.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program: Adult Treatment Panel III Report. Bethesda, Md: National Heart, Lung, and Blood Institute; 2001. Publication 01-3095.
15. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
16. Koenig W, Sund M, Fröhlich M, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99:237-242.
17. Stone NJ, Blum CR. Management of Lipids in Clinical Practice. 4th ed. Caddo, Okla: Professional Communications, Inc.; 2002.
18. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol. 1998;81:18B-25B.